Corrigendum to “Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension” [J Hepatol 62 (2015) 325–331]
Mookerjee RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, Davies N, Sharma V, Iwakiri Y, Jalan R. Corrigendum to “Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension” [J Hepatol 62 (2015) 325–331]. Journal Of Hepatology 2017, 67: 1124. PMID: 28893453, DOI: 10.1016/j.jhep.2017.08.004.Peer-Reviewed Original ResearchComparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis
Shao M, Tian T, Zhu X, Ming Y, Iwakiri Y, Ye S, Ye Q. Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis. Oncotarget 2017, 5: 66426-66437. PMID: 29029524, PMCID: PMC5630424, DOI: 10.18632/oncotarget.19815.Peer-Reviewed Original ResearchAntibody induction therapyKidney transplant recipientsAlemtuzumab treatmentInduction therapyATG groupTransplant recipientsAdverse effectsCochrane Library databasesSerious adverse effectsTreatment of kidneySystematic literature searchAcute rejectionKidney transplantationCytomegalovirus infectionRenal functionPatient survivalGeneral populationLibrary databasesComparative efficacyTreatment efficacyLiterature searchTherapy studiesTherapyEfficacyTreatment